HomeInsightsResults

Jagsonpal Pharmaceuticals Ltd Quarterly Result

Jagsonpal Pharmaceuticals Ltd Quarterly Result

stocks purchased

₹ 1.6 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

25.6 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM

Net Profit

₹ 11.46

Last updated on: Nov 23, 2024

Key Highlights

  • The revenue of Jagsonpal Pharmaceuticals Ltd for the Sep '24 is ₹ 76.35 crore as compare to the Jun '24 revenue of ₹ 62.88 crore. This represent the growth of 21.421751%.
  • The ebitda of Jagsonpal Pharmaceuticals Ltd for the Sep '24 is ₹ 17.94 crore as compare to the Jun '24 ebitda of ₹ 8.4 crore. This represent the growth of 113.57145%.
  • The net profit of Jagsonpal Pharmaceuticals Ltd for the Sep '24 is ₹ 11.46 crore as compare to the Jun '24 net profit of ₹ 5.33 crore. This represent the growth of 115.009384%.

Results Analysis

Market Price of Jagsonpal Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Jagsonpal Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 2024640.2
21 Nov 2024591.65
19 Nov 2024578.1
18 Nov 2024591.7
14 Nov 2024533.2
13 Nov 2024531.9
12 Nov 2024561.25
11 Nov 2024570.15
08 Nov 2024590.8
07 Nov 2024598.75

Historical Revenue of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Jagsonpal Pharmaceuticals Ltd News Hub

News

Jagsonpal Pharmaceuticals to table results

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

17 Oct 202412:13

News

Jagsonpal Pharmaceuticals AGM scheduled

Jagsonpal Pharmaceuticals announced that the 45th Annual General Meeting (AGM) of the comp...

Read more

13 Aug 202414:22

News

Jagsonpal Pharmaceuticals declare Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

01 Aug 202411:06

News

Jagsonpal Pharmaceuticals completes acquisition of India and Bhutan biz of Yash Pharma

Jagsonpal Pharmaceuticals completed the acquisition of India & Bhutan business of Yash Pha...

Read more

31 May 202414:15

News

Board of Jagsonpal Pharmaceuticals recommends final dividend

Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meet...

Read more

21 May 202409:56

News

Jagsonpal Pharmaceuticals Ltd leads losers in 'B' group

Pakka Ltd, IFGL Refractories Ltd, Mangalore Chemicals & Fertilizers Ltd and SBC Exports Lt...

Read more

05 Feb 202414:45

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQ's For Jagsonpal Pharmaceuticals Ltd Quarterly Result

What is the EPS of Jagsonpal Pharmaceuticals Ltd stock?

The Earnings Per Share (EPS) of Jagsonpal Pharmaceuticals Ltd is 10.09. An EPS is the amount of net income attributed to each share of a common stock.

How is Jagsonpal Pharmaceuticals Ltd EPS calculated?

The EPS of Jagsonpal Pharmaceuticals Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Jagsonpal Pharmaceuticals Ltd report its EPS?

Jagsonpal Pharmaceuticals Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Jagsonpal Pharmaceuticals Ltd EPS?

Factors that influence the EPS of Jagsonpal Pharmaceuticals Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Jagsonpal Pharmaceuticals Ltd EPS growth indicate future performance?

Yes, consistent growth in Jagsonpal Pharmaceuticals Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*